Eden Biodesign and ImmunoBiology (ImmBio) develop next generation vaccine for the prevention of influenza
21-Mar-2007
Graham Clarke, CEO of ImmBio said: "Working with Eden Biodesign will allow us to rapidly advance the next generation influenza vaccine forward towards a Clinical Trial Application and is consistent with our aggressive timelines for bringing our viral lead product to the clinic. We are delighted for the development of our leading influenza programme to be managed by Eden Biodesign at their state of the art facility in Liverpool."
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.